Coronavirus Trend Helps Improve Krka’s EBIT By 85%
As Prescription Pharmaceutical Sales Shoot Up In Q1
Slovenian firm Krka saw an increased demand for its prescription product portfolio during the quarter, which boosted group sales by more than a fifth. The company’s bottom line was a slightly more complex tale, as currency exposure in Russia wiped out significant gains in Krka’s EBIT.
